Peg-IFN-alfa-2a

DRUG2 trials

Sponsors

Tibotec BVBA

Conditions

Chronic Hepatitis CHepatitis C, Chronic

Phase 2

An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

CompletedNCT00528528

Tibotec BVBAChronic Hepatitis C

Start: 2007-10-31End: 2009-08-31Updated: 2014-06-25

Phase 3

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

CompletedNCT00703118

Tibotec BVBAHepatitis C, Chronic

Start: 2008-10-31End: 2010-07-31Updated: 2014-01-22

Related Papers

Telaprevir for retreatment of HCV infection.

2011-06-011102 citations